Results 121 to 130 of about 40,241 (253)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data [PDF]

, 2019
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdés Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches‐Arenas, Federico Argüelles‐Arias   +9 more
openalex   +1 more source

Fear of safety compromise with biosimilar anti-VEGF—perception or truth [PDF]

, 2022
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D. Kuppermann   +4 more
openalex   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Biosimilars: Patient Perspectives, Challenges and Emerging Solutions: Current Opinions [PDF]

, 2019
Frapaise FX
openalex   +1 more source

Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open‐Label, Parallel‐Group Study

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract ABP 654, a biosimilar to ustekinumab reference product, is available in a prefilled syringe (PFS) for subcutaneous (SC) use. The ABP 654 autoinjector pen (AIP) has recently been developed with an aim to improve the injection experience for patients and caregivers.
Vincent Chow, Peter J. Winkle, Daniel T. Mytych, Jia Cao, Carolina Barragan, Alexander Colbert, Shalini Gupta, Waldemar Radziszewski, Janet Franklin   +8 more
wiley   +1 more source

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar, Shuying Yang, Brendan Johnson, Sandra A.G. Visser, Paul van den Berg, Martijn van Noort, Teun M. Post   +6 more
wiley   +1 more source

Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR‐T Therapy

Engineering in Life Sciences, Volume 26, Issue 2, February 2026.
ABSTRACT Autologous chimeric antigen receptor (CAR)‐T therapies have given hope to many cancer patients whose other lines of treatment have failed. Unfortunately, limited manufacturing capability has resulted in many patients dying while on a waitlist.
B. Wayne Bequette
wiley   +1 more source

AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY) [PDF]

, 2023
O. Hagege, Thierry Lequerré, Christian Marcelli, R. Varin, D. Alcaix, Anne‐Joëlle Weber, Sorina‐Dana Mihailescu, E. Duhamel, O. Vittecoq   +8 more
openalex   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach [PDF]

, 2017
Francesco Lanza, Francesco Saraceni, Annalisa Pezzi, Massimo Martino, Alberto Bosi, Nicola Cascavilla, Pellegrino Musto, Eliana Zuffa, Monica Tani, Claudia Cellini, Daniele Laszlò, Francesca Bonifazi, on behalf of GITMO (Italian Society for Transplantation)   +12 more
openalex   +1 more source